{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T19:32:04Z","timestamp":1783971124747,"version":"3.55.0"},"reference-count":175,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001171","name":"Cancer Institute NSW","doi-asserted-by":"publisher","award":["14\/TPG\/1-05"],"award-info":[{"award-number":["14\/TPG\/1-05"]}],"id":[{"id":"10.13039\/501100001171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1148595"],"award-info":[{"award-number":["1148595"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1080521"],"award-info":[{"award-number":["1080521"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.blre.2020.100653","type":"journal-article","created":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T19:27:24Z","timestamp":1579289244000},"page":"100653","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Peripheral neuropathy in hematologic malignancies \u2013 Past, present and future"],"prefix":"10.1016","volume":"43","author":[{"given":"Tiffany","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah C.","family":"Timmins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillard M.","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna B.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.blre.2020.100653_bb0005","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1529-8027.2008.00193.x","article-title":"Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy","volume":"13","author":"Chaudhry","year":"2008","journal-title":"J Peripher Nerv Syst"},{"issue":"8","key":"10.1016\/j.blre.2020.100653_bb0010","first-page":"2261","article-title":"Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review","volume":"22","author":"Mols","year":"2014","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.blre.2020.100653_bb0015","first-page":"419","article-title":"Chemotherapy-induced peripheral neurotoxicity: a critical analysis","volume":"63","author":"Park","year":"2013","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.blre.2020.100653_bb0020","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ejca.2009.12.008","article-title":"Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools","volume":"46","author":"Cavaletti","year":"2010","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.blre.2020.100653_bb0025","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1023\/A:1008344507482","article-title":"Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy","volume":"9","author":"Postma","year":"1998","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.blre.2020.100653_bb0030","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1529-8027.2010.00292.x","article-title":"Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties","volume":"15","author":"Griffith","year":"2010","journal-title":"J Peripher Nerv Syst"},{"issue":"1","key":"10.1016\/j.blre.2020.100653_bb0035","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.blre.2020.100653_bb0040","first-page":"548","article-title":"Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature","volume":"69","author":"Ebell","year":"2004","journal-title":"Am Fam Physician"},{"issue":"3, Neurology of Systemic Disease","key":"10.1016\/j.blre.2020.100653_bb0045","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1212\/CON.0000000000000468","article-title":"Neurologic complications of lymphoma, leukemia, and paraproteinemias","volume":"23","author":"Mauermann","year":"2017","journal-title":"Continuum (Minneapolis, Minn)"},{"issue":"2","key":"10.1016\/j.blre.2020.100653_bb0050","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1017\/S0317167100011483","article-title":"The neuropathies of Waldenstrom\u2019s macroglobulinemia (WM) and IgM-MGUS","volume":"38","author":"Klein","year":"2011","journal-title":"Can J Neurol Sci"},{"issue":"7","key":"10.1016\/j.blre.2020.100653_bb0055","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s10072-016-2542-9","article-title":"An observational study assessing peripheral neuropathy related to multiple myeloma","volume":"37","author":"Leone","year":"2016","journal-title":"Neurol Sci"},{"issue":"21","key":"10.1016\/j.blre.2020.100653_bb0060","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1200\/JCO.2008.18.3087","article-title":"Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy","volume":"27","author":"Richardson","year":"2009","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.blre.2020.100653_bb0065","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1200\/JCO.2013.54.5418","article-title":"Subclinical peripheral neuropathy in patients with multiple myeloma before chemotherapy is correlated with decreased fingertip innervation density","volume":"32","author":"Kosturakis","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2020.100653_bb0070","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2016.153064","article-title":"Peripheral neuropathies in chronic lymphocytic leukemia: a single center experience on 816 patients","volume":"102","author":"Briani","year":"2017","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.blre.2020.100653_bb0075","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/mus.20163","article-title":"Lymphoma and peripheral neuropathy: a clinical review","volume":"31","author":"Kelly","year":"2005","journal-title":"Muscle Nerve"},{"issue":"7","key":"10.1016\/j.blre.2020.100653_bb0080","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/jnnp.2007.125930","article-title":"Neuropathy in lymphoma: a relationship between the pattern of neuropathy, type of lymphoma and prognosis?","volume":"79","author":"Viala","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"17","key":"10.1016\/j.blre.2020.100653_bb0085","first-page":"6316","article-title":"The proteasome as a target for cancer therapy","volume":"9","author":"Voorhees","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.blre.2020.100653_bb0090","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/leu.2011.346","article-title":"Management of treatment-emergent peripheral neuropathy in multiple myeloma","volume":"26","author":"Richardson","year":"2012","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.blre.2020.100653_bb0095","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.blre.2020.100653_bb0100","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2020.100653_bb0105","article-title":"Bortezomib for the treatment of multiple myeloma","volume":"4","author":"Scott","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.blre.2020.100653_bb0110","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(10)70068-1","article-title":"Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues","volume":"11","author":"Delforge","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2020.100653_bb0115","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.6004\/jnccn.2010.0115","article-title":"Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia","volume":"8","author":"Richardson","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"10.1016\/j.blre.2020.100653_bb0120","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10286-012-0164-8","article-title":"Bortezomib-induced severe autonomic neuropathy","volume":"22","author":"Stratogianni","year":"2012","journal-title":"Clin Auton Res"},{"issue":"11","key":"10.1016\/j.blre.2020.100653_bb0125","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/j.clinph.2008.08.007","article-title":"Immune-mediated neuropathies in myeloma patients treated with bortezomib","volume":"119","author":"Ravaglia","year":"2008","journal-title":"Clin Neurophysiol"},{"issue":"Suppl. 2","key":"10.1016\/j.blre.2020.100653_bb0130","first-page":"S52","article-title":"Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: from pathogenesis to treatment","volume":"24","author":"Velasco","year":"2019","journal-title":"J Peripher Nerv Syst"},{"issue":"2","key":"10.1016\/j.blre.2020.100653_bb0135","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12640-009-9086-1","article-title":"Bortezomib induces the formation of nuclear poly(A) RNA granules enriched in Sam68 and PABPN1 in sensory ganglia neurons","volume":"17","author":"Casafont","year":"2010","journal-title":"Neurotox Res"},{"issue":"8","key":"10.1016\/j.blre.2020.100653_bb0140","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1038\/leu.2015.80","article-title":"Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma","volume":"29","author":"Mai","year":"2015","journal-title":"Leukemia"},{"issue":"10068","key":"10.1016\/j.blre.2020.100653_bb0145","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.blre.2020.100653_bb0150","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S1470-2045(13)70398-X","article-title":"Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study","volume":"14","author":"Dimopoulos","year":"2013","journal-title":"Lancet Oncol"},{"issue":"33","key":"10.1016\/j.blre.2020.100653_bb0155","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2014.58.7618","article-title":"Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens","volume":"33","author":"Niesvizky","year":"2015","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.blre.2020.100653_bb0160","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1182\/blood-2011-05-355081","article-title":"Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma","volume":"118","author":"Moreau","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2020.100653_bb0165","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study","volume":"120","author":"Rosinol","year":"2012","journal-title":"Blood"},{"issue":"9758","key":"10.1016\/j.blre.2020.100653_bb0170","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.blre.2020.100653_bb0175","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2141.2008.07573.x","article-title":"Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline","volume":"144","author":"Richardson","year":"2009","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.blre.2020.100653_bb0180","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1600-0609.2010.01533.x","article-title":"Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study","volume":"86","author":"Dimopoulos","year":"2011","journal-title":"Eur J Haematol"},{"issue":"5","key":"10.1016\/j.blre.2020.100653_bb0185","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/bjh.14754","article-title":"Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma","volume":"178","author":"Kumar","year":"2017","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2020.100653_bb0190","doi-asserted-by":"crossref","first-page":"329","DOI":"10.5414\/CP202714","article-title":"Efficacy and safety of subcutaneous versus intravenous bortezomib in multiple myeloma: a meta-analysis","volume":"55","author":"Hu","year":"2017","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.blre.2020.100653_bb0195","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11596-018-1844-y","article-title":"Subcutaneous versus intravenous bortezomib administration for multiple myeloma patients: a meta-analysis","volume":"38","author":"Mu","year":"2018","journal-title":"Curr Med Sci"},{"issue":"11","key":"10.1016\/j.blre.2020.100653_bb0200","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1007\/s00277-018-3435-1","article-title":"The role of bortezomib in newly diagnosed diffuse large B cell lymphoma: a meta-analysis","volume":"97","author":"Lin","year":"2018","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.blre.2020.100653_bb0205","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30935-5","article-title":"Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial","volume":"20","author":"Davies","year":"2019","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.blre.2020.100653_bb0210","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1002\/cncr.32289","article-title":"Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance)","volume":"215","author":"Blum","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2020.100653_bb0215","first-page":"1","article-title":"A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma","author":"Martin","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.blre.2020.100653_bb0220","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.blre.2020.100653_bb0225","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.blre.2020.100653_bb0230","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.blre.2020.100653_bb0235","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/bjh.15679","article-title":"Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed\/refractory multiple myeloma","volume":"184","author":"Kumar","year":"2019","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2020.100653_bb0240","first-page":"167","article-title":"Safety of proteasome inhibitors for treatment of multiple myeloma","volume":"16","author":"Schlafer","year":"2017","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"10.1016\/j.blre.2020.100653_bb0245","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/0300985809358423","article-title":"Effect of proteasome inhibitors with different chemical structures on the ubiquitin-proteasome system in vitro","volume":"47","author":"Csizmadia","year":"2010","journal-title":"Vet Pathol"},{"issue":"9","key":"10.1016\/j.blre.2020.100653_bb0250","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-10-1950","article-title":"Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events","volume":"17","author":"Arastu-Kapur","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.blre.2020.100653_bb0255","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-34507-3","article-title":"Proteomic approach for understanding milder neurotoxicity of carfilzomib against bortezomib","volume":"8","author":"Karademir","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.blre.2020.100653_bb0260","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17596-4","article-title":"Milder degenerative effects of carfilzomib vs. bortezomib in the drosophila model: a link to clinical adverse events","volume":"7","author":"Tsakiri","year":"2017","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.blre.2020.100653_bb0265","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1074\/mcp.M116.059709","article-title":"Specificity of protein covalent modification by the electrophilic proteasome inhibitor carfilzomib in human cells","volume":"15","author":"Federspiel","year":"2016","journal-title":"Mol Cell Proteomics"},{"issue":"3","key":"10.1016\/j.blre.2020.100653_bb0270","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1084\/jem.173.3.699","article-title":"Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes","volume":"173","author":"Sampaio","year":"1991","journal-title":"J Exp Med"},{"issue":"9","key":"10.1016\/j.blre.2020.100653_bb0275","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D\u2019Amato","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.blre.2020.100653_bb0280","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1084\/jem.187.11.1885","article-title":"Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset","volume":"187","author":"Haslett","year":"1998","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.blre.2020.100653_bb0285","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/BF03401909","article-title":"Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity","volume":"2","author":"Corral","year":"1996","journal-title":"Mol Med"},{"issue":"12","key":"10.1016\/j.blre.2020.100653_bb0290","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1212\/01.WNL.0000037480.59194.85","article-title":"Thalidomide-induced neuropathy","volume":"59","author":"Chaudhry","year":"2002","journal-title":"Neurology"},{"issue":"27","key":"10.1016\/j.blre.2020.100653_bb0295","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1200\/JCO.2006.05.6689","article-title":"Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring","volume":"24","author":"Mileshkin","year":"2006","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.blre.2020.100653_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(18)30149-2","article-title":"Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial","volume":"5","author":"van de Donk","year":"2018","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.blre.2020.100653_bb0305","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0268-960X(02)00031-0","article-title":"Thalidomide treatment in multiple myeloma","volume":"16","author":"Strasser","year":"2002","journal-title":"Blood Rev"},{"issue":"8","key":"10.1016\/j.blre.2020.100653_bb0310","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.amjcard.2003.12.061","article-title":"Bradycardia during therapy for multiple myeloma with thalidomide","volume":"93","author":"Fahdi","year":"2004","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.blre.2020.100653_bb0315","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/j.1365-2141.2005.05914.x","article-title":"A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma","volume":"132","author":"Glasmacher","year":"2006","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2020.100653_bb0320","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00277-017-2927-8","article-title":"The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: results from the population-based PROFILES registry","volume":"96","author":"Beijers","year":"2017","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.blre.2020.100653_bb0325","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1600-0609.2004.00382.x","article-title":"Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma","volume":"74","author":"Tosi","year":"2005","journal-title":"Eur J Haematol"},{"issue":"9","key":"10.1016\/j.blre.2020.100653_bb0330","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1038\/leu.2017.35","article-title":"Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA\/GEM trial","volume":"31","author":"Rosinol","year":"2017","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.blre.2020.100653_bb0335","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/leu.2009.147","article-title":"Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.blre.2020.100653_bb0340","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood-2015-11-679415","article-title":"Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma","volume":"127","author":"Zweegman","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2020.100653_bb0345","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3109\/10428194.2013.838232","article-title":"Bortezomib in combination with thalidomide or lenalidomide or doxorubicin regimens for the treatment of multiple myeloma: a meta-analysis of 14 randomized controlled trials","volume":"55","author":"Wang","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.blre.2020.100653_bb0350","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1212\/WNL.0000000000003093","article-title":"Lenalidomide long-term neurotoxicity: clinical and neurophysiologic prospective study","volume":"87","author":"Dalla Torre","year":"2016","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.blre.2020.100653_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(18)30131-5","article-title":"Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study","volume":"5","author":"Tilly","year":"2018","journal-title":"Lancet Haematol"},{"issue":"11","key":"10.1016\/j.blre.2020.100653_bb0360","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41408-018-0145-9","article-title":"Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials","volume":"8","author":"Castellino","year":"2018","journal-title":"Blood Cancer J"},{"issue":"17","key":"10.1016\/j.blre.2020.100653_bb0365","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.2217\/fon-2016-0184","article-title":"Pomalidomide in the management of relapsed multiple myeloma","volume":"12","author":"Touzeau","year":"2016","journal-title":"Future Oncol"},{"issue":"11","key":"10.1016\/j.blre.2020.100653_bb0370","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"San Miguel","year":"2013","journal-title":"Lancet Oncol"},{"issue":"30","key":"10.1016\/j.blre.2020.100653_bb0375","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/JCO.2009.23.6802","article-title":"Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma","volume":"27","author":"Lacy","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2020.100653_bb0380","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2016-02-700872","article-title":"Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma","volume":"128","author":"Dimopoulos","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2020.100653_bb0385","first-page":"1231","article-title":"Vinca alkaloids","volume":"4","author":"Moudi","year":"2013","journal-title":"Int J Prev Med"},{"issue":"1","key":"10.1016\/j.blre.2020.100653_bb0390","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF01050259","article-title":"Long-term effects of vincristine on the peripheral nervous system","volume":"15","author":"Postma","year":"1993","journal-title":"J Neurooncol"},{"issue":"6","key":"10.1016\/j.blre.2020.100653_bb0395","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1212\/01.WNL.0000154642.45474.28","article-title":"Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening","volume":"64","author":"Verstappen","year":"2005","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.blre.2020.100653_bb0400","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1002\/1097-0142(19940515)73:10<2515::AID-CNCR2820731011>3.0.CO;2-G","article-title":"Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas","volume":"73","author":"Haim","year":"1994","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.blre.2020.100653_bb0405","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/01616412.2016.1139321","article-title":"Vincristine-induced neurotoxicity: electrophysiological features in children","volume":"38","author":"Yildiz","year":"2016","journal-title":"Neurol Res"},{"issue":"12","key":"10.1016\/j.blre.2020.100653_bb0410","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26677","article-title":"Vincristine-induced neuropathy in pediatric patients with acute lymphoblastic leukemia in Oman: Frequent autonomic and more severe cranial nerve involvement","volume":"64","author":"Nazir","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"5977","key":"10.1016\/j.blre.2020.100653_bb0415","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/bmj.3.5977.207","article-title":"Vincristine-induced autonomic neuropathy","volume":"3","author":"Hancock","year":"1975","journal-title":"Br Med J"},{"issue":"3","key":"10.1016\/j.blre.2020.100653_bb0420","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1529-8027.2009.00230.x","article-title":"Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia","volume":"14","author":"Ramchandren","year":"2009","journal-title":"J Peripher Nerv Syst"},{"issue":"1","key":"10.1016\/j.blre.2020.100653_bb0425","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/jns.12114","article-title":"Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia","volume":"20","author":"Lavoie Smith","year":"2015","journal-title":"J Peripher Nerv Syst"},{"issue":"1","key":"10.1016\/j.blre.2020.100653_bb0430","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/pbc.26204","article-title":"Short-term recovery of chemotherapy-induced peripheral neuropathy after treatment for pediatric non-CNS cancer","volume":"64","author":"Gilchrist","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2020.100653_bb0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijporl.2019.04.001","article-title":"Vincristine-induced vocal cord paresis and paralysis in children","volume":"123","author":"Zavala","year":"2019","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"4","key":"10.1016\/j.blre.2020.100653_bb0440","first-page":"252","article-title":"Risk factors for early-onset peripheral neuropathy caused by vincristine in patients with a first administration of R-CHOP or R-CHOP-like chemotherapy","volume":"6","author":"Okada","year":"2014","journal-title":"J Clin Med Res"},{"issue":"1","key":"10.1016\/j.blre.2020.100653_bb0445","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/mpo.10105","article-title":"Vincristine neurotoxicity in the presence of hereditary neuropathy","volume":"40","author":"Trobaugh-Lotrario","year":"2003","journal-title":"Med Pediatr Oncol"},{"issue":"6","key":"10.1016\/j.blre.2020.100653_bb0450","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1158\/1078-0432.CCR-18-2435","article-title":"Brentuximab vedotin plus chemotherapy in North American subjects with newly diagnosed stage III or IV hodgkin hymphoma","volume":"25","author":"Ramchandren","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.blre.2020.100653_bb0455","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00277-016-2611-4","article-title":"Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era","volume":"95","author":"Jalali","year":"2016","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.blre.2020.100653_bb0460","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2008.17.0910","article-title":"ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin\u2019s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.blre.2020.100653_bb0465","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2009.23.3239","article-title":"Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin\u2019s Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244","volume":"27","author":"Hoskin","year":"2009","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.blre.2020.100653_bb0470","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/s00277-005-1082-9","article-title":"Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma, results of a phase II single center study","volume":"84","author":"Muller-Beissenhirtz","year":"2005","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.blre.2020.100653_bb0475","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/bjh.12379","article-title":"High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study","volume":"162","author":"Gyan","year":"2013","journal-title":"Br J Haematol"},{"issue":"5\u20136","key":"10.1016\/j.blre.2020.100653_bb0480","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3109\/10428199609054778","article-title":"Vinorelbine: a new promising drug in Hodgkin\u2019s disease","volume":"22","author":"Devizzi","year":"1996","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.blre.2020.100653_bb0485","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.leukres.2015.03.015","article-title":"Neurotoxicity of stem cell mobilization chemotherapy with vinorelbine in myeloma patients after bortezomib treatment","volume":"39","author":"Keller","year":"2015","journal-title":"Leuk Res"},{"issue":"8","key":"10.1016\/j.blre.2020.100653_bb0490","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JOP.2017.021907","article-title":"Adult t-cell leukemia\/lymphoma","volume":"13","author":"Mehta-Shah","year":"2017","journal-title":"J Oncol Pract"},{"issue":"12","key":"10.1016\/j.blre.2020.100653_bb0495","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1016\/j.leukres.2009.04.014","article-title":"Vindesine-induced neuropathy mimicking Guillain-Barre syndrome","volume":"33","author":"Liu","year":"2009","journal-title":"Leuk Res"},{"issue":"22","key":"10.1016\/j.blre.2020.100653_bb0500","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1182\/blood-2014-06-537514","article-title":"Brentuximab vedotin","volume":"124","author":"Ansell","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2020.100653_bb0505","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"issue":"10168","key":"10.1016\/j.blre.2020.100653_bb0510","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.blre.2020.100653_bb0515","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1002\/cpt.1530","article-title":"Population pharmacokinetic modeling and exposure-response assessment for the antibody-drug conjugate brentuximab vedotin in hodgkin hymphoma in the phase III ECHELON-1 study","volume":"106","author":"Suri","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.blre.2020.100653_bb0520","first-page":"1","article-title":"Clinical and neurophysiological serial assessments of brentuximab vedotin-associated peripheral neuropathy","author":"Mariotto","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.blre.2020.100653_bb0525","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11060-017-2389-9","article-title":"Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of mycosis fungoides and sezary syndrome","volume":"132","author":"Corbin","year":"2017","journal-title":"J Neurooncol"},{"issue":"8","key":"10.1016\/j.blre.2020.100653_bb0530","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.72","article-title":"Brentuximab vedotin: axonal microtubule\u2019s Apollyon","volume":"5","author":"Mariotto","year":"2015","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.blre.2020.100653_bb0535","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.3109\/10428194.2013.773997","article-title":"Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin","volume":"54","author":"Pastorelli","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.blre.2020.100653_bb0540","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/psp4.12192","article-title":"Time-to-event analysis of polatuzumab vedotin-induced peripheral neuropathy to assist in the comparison of clinical dosing regimens","volume":"6","author":"Lu","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"25","key":"10.1016\/j.blre.2020.100653_bb0545","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","article-title":"Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"130","author":"Pro","year":"2017","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.blre.2020.100653_bb0550","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s40265-019-01175-0","article-title":"Polatuzumab vedotin: first global approval [published correction appears in Drugs. 2019;79(16):1829]","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.blre.2020.100653_bb0555","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1182\/blood.V81.1.84.84","article-title":"Three new monoclonal antibodies that define a unique antigen associated with prolymphocytic leukemia\/non-Hodgkin\u2019s lymphoma and are effectively internalized after binding to the cell surface antigen","volume":"81","author":"Okazaki","year":"1993","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2020.100653_bb0560","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1038\/leu.2015.48","article-title":"Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes","volume":"29","author":"Pfeifer","year":"2015","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.blre.2020.100653_bb0565","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","article-title":"Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","volume":"16","author":"Palanca-Wessels","year":"2015","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.blre.2020.100653_bb0570","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1470-2045(19)30091-9","article-title":"Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study","volume":"20","author":"Tilly","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.blre.2020.100653_bb0575","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(19)30026-2","article-title":"Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.blre.2020.100653_bb0580","article-title":"Interventions for preventing neuropathy caused by cisplatin and related compounds","author":"Albers","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.blre.2020.100653_bb0585","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00277-013-1952-5","article-title":"DCEP for relapsed or refractory multiple myeloma after therapy with novel agents","volume":"93","author":"Park","year":"2014","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.blre.2020.100653_bb0590","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/bjh.12325","article-title":"D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma","volume":"161","author":"Gerrie","year":"2013","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2020.100653_bb0595","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1080\/10428194.2016.1193852","article-title":"Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed\/refractory diffuse large B-cell lymphoma and hodgkin lymphoma","volume":"58","author":"Moccia","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.blre.2020.100653_bb0600","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/ajh.23835","article-title":"Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study","volume":"89","author":"Tacchetti","year":"2014","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.blre.2020.100653_bb0605","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMoa053583","article-title":"Thalidomide and hematopoietic-cell transplantation for multiple myeloma","volume":"354","author":"Barlogie","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2020.100653_bb0610","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.seminoncol.2005.12.010","article-title":"Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy","volume":"33","author":"Hausheer","year":"2006","journal-title":"Semin Oncol"},{"issue":"8","key":"10.1016\/j.blre.2020.100653_bb0615","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1182\/blood-2007-10-117457","article-title":"Thalidomide for treatment of multiple myeloma: 10 years later","volume":"111","author":"Palumbo","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2020.100653_bb0620","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3324\/haematol.2009.012674","article-title":"Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations","volume":"95","author":"Mohty","year":"2010","journal-title":"Haematologica"},{"issue":"19","key":"10.1016\/j.blre.2020.100653_bb0625","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood-2017-12-821009","article-title":"Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas","volume":"131","author":"Fanale","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2020.100653_bb0630","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26471","article-title":"Vincristine-induced peripheral neuropathy in survivors of childhood acute lymphoblastic leukaemia","volume":"64","author":"Tay","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"10.1016\/j.blre.2020.100653_bb0635","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/ana.24265","article-title":"Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy","volume":"76","author":"Beutler","year":"2014","journal-title":"Ann Neurol"},{"issue":"19","key":"10.1016\/j.blre.2020.100653_bb0640","doi-asserted-by":"crossref","first-page":"5757","DOI":"10.1158\/1078-0432.CCR-16-3224","article-title":"Clinical and genome-wide analysis of cisplatin-induced peripheral neuropathy in survivors of adult-onset cancer","volume":"23","author":"Dolan","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.blre.2020.100653_bb0645","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/jns.12110","article-title":"Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis","volume":"20","author":"Terrazzino","year":"2015","journal-title":"J Peripher Nerv Syst"},{"issue":"5","key":"10.1016\/j.blre.2020.100653_bb0650","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41397-019-0093-1","article-title":"Concerns regarding use of patient-reported outcomes in biomarker studies of chemotherapy-induced peripheral neuropathy","volume":"19","author":"Hertz","year":"2019","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.blre.2020.100653_bb0655","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.critrevonc.2017.09.009","article-title":"The molecular genetics of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"120","author":"Cliff","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"issue":"Suppl. 2","key":"10.1016\/j.blre.2020.100653_bb0660","article-title":"The toxic neuropathy consortium of the Peripheral Nerve Society","volume":"24","author":"Argyriou","year":"2019","journal-title":"J Peripher Nerv Syst"},{"issue":"10","key":"10.1016\/j.blre.2020.100653_bb0665","first-page":"3729","article-title":"Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview","volume":"27","author":"Chan","year":"2019","journal-title":"Support Care Cancer"},{"issue":"10","key":"10.1016\/j.blre.2020.100653_bb0670","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1182\/blood-2006-10-054528","article-title":"Ancestry and pharmacogenetics of antileukemic drug toxicity","volume":"109","author":"Kishi","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2020.100653_bb0675","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/pbc.22845","article-title":"Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia","volume":"56","author":"Egbelakin","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"10.1016\/j.blre.2020.100653_bb0680","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2217\/pgs.14.68","article-title":"Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia","volume":"15","author":"Ceppi","year":"2014","journal-title":"Pharmacogenomics"},{"issue":"7","key":"10.1016\/j.blre.2020.100653_bb0685","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2217\/pgs-2016-0001","article-title":"Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia","volume":"17","author":"Lopez-Lopez","year":"2016","journal-title":"Pharmacogenomics"},{"issue":"2","key":"10.1016\/j.blre.2020.100653_bb0690","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/cpt.1179","article-title":"Pharmacogenomics of vincristine-induced peripheral neuropathy implicates pharmacokinetic and inherited neuropathy genes","volume":"105","author":"Wright","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.blre.2020.100653_bb0695","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/00043426-200304000-00010","article-title":"Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study","volume":"25","author":"Chauvenet","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"issue":"15","key":"10.1016\/j.blre.2020.100653_bb0700","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2217\/pgs-2018-0093","article-title":"Genetic risk factors for VIPN in childhood acute lymphoblastic leukemia patients identified using whole-exome sequencing","volume":"19","author":"Abaji","year":"2018","journal-title":"Pharmacogenomics"},{"issue":"6","key":"10.1016\/j.blre.2020.100653_bb0705","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/cpt.1324","article-title":"Genetic variants associated with vincristine-induced peripheral neuropathy in two populations of children with acute lymphoblastic leukemia","volume":"105","author":"Li","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.blre.2020.100653_bb0710","article-title":"Variants in vincristine pharmacodynamic genes involved in neurotoxicity at induction phase in the therapy of pediatric acute lymphoblastic leukemia","volume":"6","author":"Martin-Guerrero","year":"2019","journal-title":"Pharmacogenomics J"},{"issue":"8","key":"10.1016\/j.blre.2020.100653_bb0715","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jama.2015.0894","article-title":"Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia","volume":"313","author":"Diouf","year":"2015","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.blre.2020.100653_bb0720","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/cpt.506","article-title":"An inherited genetic variant in CEP72 promoter predisposes to vincristine-induced peripheral neuropathy in adults with acute lymphoblastic leukemia","volume":"101","author":"Stock","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.blre.2020.100653_bb0725","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/FPC.0000000000000191","article-title":"Lack of association of the CEP72 rs924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population","volume":"26","author":"Gutierrez-Camino","year":"2016","journal-title":"Pharmacogenet Genomics"},{"issue":"5","key":"10.1016\/j.blre.2020.100653_bb0730","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.14678","article-title":"Pharmacogenetic association with neurotoxicity in Hispanic children with acute lymphoblastic leukaemia","volume":"181","author":"McClain","year":"2018","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.blre.2020.100653_bb0735","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/FPC.0000000000000345","article-title":"Genetic polymorphisms in candidate genes are not associated with increased vincristine-related peripheral neuropathy in Arab children treated for acute childhood leukemia: a single institution study","volume":"28","author":"Zgheib","year":"2018","journal-title":"Pharmacogenet Genomics"},{"issue":"11","key":"10.1016\/j.blre.2020.100653_bb0740","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S1470-2045(10)70206-0","article-title":"Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65\/GMMG-HD4 trial","volume":"11","author":"Broyl","year":"2010","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.blre.2020.100653_bb0745","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1200\/JCO.2010.28.0792","article-title":"Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma","volume":"29","author":"Johnson","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2020.100653_bb0750","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/hon.2337","article-title":"Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array","volume":"35","author":"Garcia-Sanz","year":"2017","journal-title":"Hematol Oncol"},{"issue":"11","key":"10.1016\/j.blre.2020.100653_bb0755","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.3324\/haematol.2011.041434","article-title":"Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients","volume":"96","author":"Corthals","year":"2011","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.blre.2020.100653_bb0760","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-4728-4","article-title":"Chemotherapy-induced peripheral neuropathy: evidence from genome-wide association studies and replication within multiple myeloma patients","volume":"18","author":"Mahmoudpour","year":"2018","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.blre.2020.100653_bb0765","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/FPC.0b013e3283436b45","article-title":"Genetic variation associated with bortezomib-induced peripheral neuropathy","volume":"21","author":"Favis","year":"2011","journal-title":"Pharmacogenet Genomics"},{"issue":"17","key":"10.1016\/j.blre.2020.100653_bb0770","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1158\/1078-0432.CCR-15-3163","article-title":"A genome-wide association study identifies a novel locus for bortezomib-induced peripheral neuropathy in european patients with multiple myeloma","volume":"22","author":"Magrangeas","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.blre.2020.100653_bb0775","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s11064-016-2007-9","article-title":"Genetic susceptibility to bortezomib-induced peripheral neuroropathy: replication of the reported candidate susceptibility loci","volume":"42","author":"Campo","year":"2017","journal-title":"Neurochem Res"},{"issue":"1","key":"10.1016\/j.blre.2020.100653_bb0780","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/hon.2391","article-title":"Bortezomib-induced peripheral neuropathy: a genome-wide association study on multiple myeloma patients","volume":"36","author":"Campo","year":"2018","journal-title":"Hematol Oncol"},{"issue":"9","key":"10.1016\/j.blre.2020.100653_bb0785","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1097\/CAD.0b013e32833db89d","article-title":"Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis","volume":"21","author":"Kanbayashi","year":"2010","journal-title":"Anticancer Drugs"},{"issue":"1","key":"10.1016\/j.blre.2020.100653_bb0795","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1529-8027.2010.00248.x","article-title":"Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients","volume":"15","author":"Velasco","year":"2010","journal-title":"J Peripher Nerv Syst"},{"issue":"5","key":"10.1016\/j.blre.2020.100653_bb0800","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/cncr.22921","article-title":"Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature","volume":"110","author":"Badros","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2020.100653_bb0805","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.critrevonc.2017.04.004","article-title":"Vincristine-induced peripheral neuropathy in children with cancer: a systematic review","volume":"114","author":"van de Velde","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.blre.2020.100653_bb0810","article-title":"Obesity as a potential risk factor for vincristine-induced peripheral neuropathy","author":"Sajdyk","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"issue":"4","key":"10.1016\/j.blre.2020.100653_bb0815","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3988\/jcn.2019.15.4.511","article-title":"Prediction of chemotherapy-induced peripheral neuropathy in patients with lymphoma and myeloma: the roles of brain-derived neurotropic factor protein levels and a gene polymorphism","volume":"15","author":"Azoulay","year":"2019","journal-title":"J Clin Neurol"},{"issue":"2","key":"10.1016\/j.blre.2020.100653_bb0820","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1067\/mcp.2001.117412","article-title":"Identification of functionally variant MDR1 alleles among European Americans and African Americans","volume":"70","author":"Kim","year":"2001","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.blre.2020.100653_bb0825","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/pbc.21435","article-title":"Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients","volume":"50","author":"Renbarger","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.blre.2020.100653_bb0830","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1177\/1534735418788667","article-title":"Acupuncture for bortezomib-induced peripheral neuropathy: not just for pain","volume":"17","author":"Zhi","year":"2018","journal-title":"Integr Cancer Ther"},{"issue":"1","key":"10.1016\/j.blre.2020.100653_bb0835","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-016-3037-z","article-title":"Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma","volume":"17","author":"Han","year":"2017","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.blre.2020.100653_bb0840","first-page":"480","article-title":"Prophylaxis of bortezomib-induced peripheral neuropathy in patients with multiple myeloma by high-dose intravenous mecobalamin","volume":"25","author":"Zhang","year":"2017","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"4","key":"10.1016\/j.blre.2020.100653_bb0845","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00280-014-2550-5","volume":"74","author":"Callander","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.blre.2020.100653_bb0850","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1177\/1534735418803758","article-title":"Prevention of bortezomib-related peripheral neuropathy with docosahexaenoic acid and alpha-lipoic acid in patients with multiple myeloma: preliminary data","volume":"17","author":"Maschio","year":"2018","journal-title":"Integr Cancer Ther"},{"issue":"13","key":"10.1016\/j.blre.2020.100653_bb0855","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.blre.2020.100653_bb0860","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/s10147-015-0810-y","article-title":"Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial","volume":"20","author":"Hirayama","year":"2015","journal-title":"Int J Clin Oncol"},{"issue":"9","key":"10.1016\/j.blre.2020.100653_bb0865","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/cncr.23008","article-title":"Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3)","volume":"110","author":"Rao","year":"2007","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.blre.2020.100653_bb0870","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1097\/j.pain.0000000000001577","article-title":"Somatosensory predictors of response to pregabalin in painful chemotherapy-induced peripheral neuropathy: a randomized, placebo-controlled, crossover study","volume":"160","author":"Hincker","year":"2019","journal-title":"Pain"},{"issue":"4","key":"10.1016\/j.blre.2020.100653_bb0875","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.2010.08264.x","article-title":"Tanespimycin with bortezomib: activity in relapsed\/refractory patients with multiple myeloma","volume":"150","author":"Richardson","year":"2010","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.blre.2020.100653_bb0880","first-page":"3849","article-title":"Exercise-based rehabilitation for cancer survivors with chemotherapy-induced peripheral neuropathy","volume":"27","author":"McCrary","year":"2019","journal-title":"Support Care Cancer"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X20300035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X20300035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:03:04Z","timestamp":1777539784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X20300035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":175,"alternative-id":["S0268960X20300035"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2020.100653","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peripheral neuropathy in hematologic malignancies \u2013 Past, present and future","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2020.100653","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100653"}}